

# The application of the levonorgestrel containing intrauterine contraceptive device in the prevention of endometrial changes induced by tamoxifen in women undergoing adjuvant therapy for breast cancer

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 13/02/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr J Konje

### Contact details

University Hospitals of Leicester  
c/o Research and Development Office  
Leicester General Hospital NHS Trust  
Leicester  
United Kingdom  
LE1 4PW  
+44 (0)116 258 4109  
[nicola.turner@uhl-tr.nhs.uk](mailto:nicola.turner@uhl-tr.nhs.uk)

## Additional identifiers

### Protocol serial number

N0123109192

# Study information

## Scientific Title

The application of the levonorgestrel containing intrauterine contraceptive device in the prevention of endometrial changes induced by tamoxifen in women undergoing adjuvant therapy for breast cancer

## Study objectives

To find out whether giving this treatment at the time of initiation of tamoxifen treatment will prevent the changes induced by this drug from developing in the first instance.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Breast cancer

## Interventions

Randomised controlled trial: prior to tamoxifen treatment, patient will receive either:

1. Levonorgestrel-containing intrauterine contraceptive device
2. Placebo

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Levonorgestrel, tamoxifen

## Primary outcome(s)

Data not yet available.

## Key secondary outcome(s))

Not provided at time of registration

## Completion date

31/12/2007

## Eligibility

### Key inclusion criteria

Data not yet available.

### Participant type(s)

Patient

### Healthy volunteers allowed

No

### Age group

Not Specified

### Sex

Female

### Key exclusion criteria

Not provided at time of registration

### Date of first enrolment

01/01/2002

### Date of final enrolment

31/12/2007

## Locations

### Countries of recruitment

United Kingdom

England

### Study participating centre

University Hospitals of Leicester

Leicester

United Kingdom

LE1 4PW

## Sponsor information

### Organisation

Department of Health (UK)

# Funder(s)

## Funder type

Government

## Funder Name

University Hospitals of Leicester NHS Trust (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2009		Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes